SecBot SecBot

Cameron’s Law

H.R. 1414 Rep. Josh Gottheimer (D-NJ-5) In committee
Bill text PDF
  1. Introduced Feb 18
  2. Committee Feb 18
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 18, 2025Next: House vote
617d ago Feb 18, 2025: Referred to the House Committee on Ways and Means.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
9companies, 57 filings
Subscribe to see spend
Member trades
3trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

9 companies
Companies by sector
Biotech & Pharma 9
Search all 9 companies, their asks and price moves Subscribe

Summary

Cameron's Law

Full summary2 paragraphs

This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions.

As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.

Library of Congress summary, Feb 18, 2025

Summary versions
  • Introduced in HouseFeb 18, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.